← All Cue Biopharma, INC filings

Cue Biopharma, INC 10-K annual reports

Annual reports — audited financials, the full risk-factor list, and management’s account of the year.

NASDAQ
CUE
Cue Biopharma, INC
10-K: Cue Biopharma Navigates Financial Hurdles, Advances Autoimmune Pipeline
Cue Biopharma reports recurring losses and going concern doubt, while advancing its autoimmune pipeline with CUE-401 nearing IND filing and CUE-501 licensed to Boehringer Ingelheim, alongside oncology asset licensing.
NASDAQ
CUE
Cue Biopharma, INC
10-K: Cue Biopharma Prioritizes Autoimmune Programs, Seeks Partnerships for Oncology Assets in 2024 10-K Filing
Cue Biopharma shifts focus to autoimmune drug candidates while exploring strategic partnerships for its oncology programs, according to its 2024 annual report.
NASDAQ
CUE
Cue Biopharma, INC
10-K: Cue Biopharma Details Common Stock Structure and Anti-Takeover Provisions in 10-K Filing
Cue Biopharma's 10-K filing outlines the details of its common stock, preferred stock, and various anti-takeover provisions designed to protect the company from hostile acquisitions.